ARTICLE | Company News
Intercell, SciGen HBV vaccine deal
December 13, 2004 8:00 AM UTC
Intercell (Vienna, Austria) and SciGen (ASX:SIE) will co-develop an HBV vaccine that combines SIE's Sci-B-Vac PreS1- and PreS2- HBV antigen with Intercell's Immunizer IC31 adjuvant. The companies will...